樂普醫療(300003.SZ)：擬分拆子公司樂普診斷至科創板上市
格隆匯 7 月 29日丨樂普醫療(300003.SZ)公佈，公司擬將其控股子公司北京樂普診斷科技股份有限公司(“樂普診斷”或“擬分拆主體”)分拆至科創板上市，此次分拆完成後不會影響對子公司樂普診斷的控制權。
樂普診斷主營業務為體外診斷試劑及儀器的研發、生產和銷售，涉及領域包括血液診斷、POCT免疫診斷、分子診斷和生化診斷等。樂普診斷已形成以血液診斷、POCT免疫診斷相關產品為核心，以分子診斷、生化診斷相關產品為重點的產業佈局。
血液診斷領域，樂普診斷已有凝血、血型、交叉配血、抗血小板藥物療效監測、常規出凝血等平台。免疫診斷領域，樂普診斷已有膠體金免疫層析、熒光免疫層析、化學發光、微流控等平台，試劑種類涉及心標、腫瘤、腎功能、炎症、甲狀腺功能、性激素等。同時，樂普診斷一直致力於試劑與儀器的共同發展，上述試劑均配套相應的檢測儀器，包括血栓彈力圖儀、全自動血小板聚集儀、膠體金免疫層析分析儀、全自動熒光定量分析儀、全自動醫用PCR分析系統和血糖儀等。
公司一直致力於為心血管疾病患者提供全面和優質的服務。公司通過研發各種技術先進、療效明確的產品和醫療技術，為心血管疾病患者、慢病管理的中老年人、醫生、家庭、社區、醫院、養老康復機構等提供各種品牌化產品、裝備和服務網絡途徑，在心血管疾病預防、診斷、藥物治療、手術治療、術後康復、慢病管理及再預防的全生命週期內為患者服務，形成了醫療器械、醫藥、醫療服務、新型醫療四大主業板塊。公司所屬子公司樂普診斷主要經營體外診斷試劑及儀器的研發、生產和銷售業務，與公司其他業務保持較高的獨立性，此次分拆樂普診斷至上交所科創板上市不會對公司其他業務的持續經營構成實質性影響。
此次分拆完成後，樂普醫療將進一步圍繞心血管患者，聚焦醫療器械、醫藥、醫療服務、新型醫療四大主業板塊，進一步深耕心血管醫療市場，提升行業競爭力。樂普診斷將成為樂普醫療獨立的體外診斷業務上市平台，通過在科創板上市拓寬融資渠道、增強資金實力，提升研發能力和行業競爭力，進而提升樂普診斷的盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
